Fispemifene

Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed.[1][2][3] It reached phase II clinical trials for this indication before development was terminated in March 2016.[1] The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.[1]

Fispemifene

Clinical data
Other names	HM-101
Identifiers
IUPAC name 2-(2-(4-((1Z)-4-Chloro-1,2-diphenylbut-1-enyl)phenoxy)ethoxy)ethanol
CAS Number	341524-89-8
PubChem CID	9954033
ChemSpider	8129643
UNII	3VZ2833V08
KEGG	D10008
ChEMBL	ChEMBL2107341
Chemical and physical data
Formula	C26H27ClO3
Molar mass	422.95 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCOCCO)/CCCl
InChI InChI=1S/C26H27ClO3/c27-16-15-25(21-7-3-1-4-8-21)26(22-9-5-2-6-10-22)23-11-13-24(14-12-23)30-20-19-29-18-17-28/h1-14,28H,15-20H2/b26-25- Key:NKZTZAQIKKGTDB-QPLCGJKRSA-N

See also

• Ospemifene

References

1. https://adisinsight.springer.com/drugs/800013715%5B%5D
2. Antonio Cano; Joacquim Calaf i Alsina; Jose Luis Duenas-Diez (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 52–. ISBN 978-3-540-34742-2.
3. Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 90–. ISBN 978-3-527-62330-3.

External links

• Fispemifene - AdisInsight